

February 12, 2016

To,
General Manager,
National Stock Exchange of India Ltd.,
Exchange Plaza, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai: 400051.

Respected Sir/Madam,

Scrip ID: KILITCH

Sub: OUTCOME OF THE BOARD MEETING HELD ON FRIDAY, FEBRUARY 12, 2016.

With the reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held on today, i.e. Friday, February 12, 2016, for which intimation was already given to you, the Board of Directors has:

- Taken on Record the Unaudited Financial Results of the Company for the quarter/nine months ended December 2015 along with the Limited Review Report as submitted by M/s. A.M. Ghelani & Co., Chartered Accountants, being the Statutory Auditors of the Company.
- Adopted the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and authorised Mr. Mukund Mehta, Managing Director of the Company to sign, enter and execute the amended Listing Agreement under said Regulations and the same shall be forwarded to BSE & NSE.

Kindly find the same in order and acknowledge the receipt of the same.

Thanking You,

Yours faithfully,

For: KILITCH DRUGS (INDIA) LIMITED


MUKUND MEHTA
Managing Director
(DIN NO: 00147876)



A.M.GHELANI & COMPANY

CHARTERED ACCOUNTANTS

AJIT M. GHELANI

B.Com. (Hons), F.C.A., GRAD. C.W.A.

CHINTAN A. GHELANI

B.Com. (Hons), F.C.A., C.S.

INDEPENDENT AUDITORS' REVIEW REPORT

To,
The Board of Directors
Kilitch Drugs (India) Limited

LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER/ NINE MONTHS ENDED 31st DECEMBER, 2015

1. We have reviewed the accompanying statement of unaudited standalone financial results of Kilitch Drugs (India) Limited for the quarter/ nine months ended 31st December, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies and has not disclosed the information required to be disclosed in terms of Clause 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company
Chartered Accountants
(Firm Registration No. 103173W)


Chintan A. Ghelani
Partner

Membership No. 104391



Place: Mumbai

Date: 12th February, 2016

Enclosed: Unaudited financial results for the quarter/ nine months ended 31st December, 2015 of Kilitch Drugs (India) Limited.

KILITCH DRUGS (INDIA) LIMITED

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER 2015

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

Rs. In Lacs

Sr. No.	Particulars	Three Months Ended			Nine Months Ended		Year ended
		31/12/15	30/09/15	31/12/14	31/12/15	31/12/14	31/03/15
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations						
	(a) Net Sales/income from operations(net of Excise)	590.46	428.73	360.81	1414.93	1521.33	1843.73
	(b) Other operating income	3.40	2.31	18.93	9.39	50.08	59.00
	Total Income from Operations (Net)	593.86	431.05	379.74	1424.32	1571.41	1902.73
2	Expenses						
	(a) Cost of materials consumed	293.04	103.26	147.74	694.66	524.53	648.59
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(44.35)	9.45	13.42	(48.14)	57.71	53.02
	(c) Employee Benefit Expenses	83.81	83.03	75.94	252.10	238.48	312.80
	(d) Depreciation and Amortisation Expenses	41.77	39.07	57.98	119.98	166.21	185.39
	(e) Export Product Registration Charges	57.16	30.90	34.81	102.71	106.97	110.13
	(f) Other Expenses	189.14	248.93	211.81	723.51	641.70	946.27
	Total Expenses	620.58	514.63	541.69	1844.81	1735.59	2256.20
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(26.72)	(83.60)	(161.95)	(420.50)	(164.18)	(353.47)
4	Other Income	43.13	17.84	70.54	118.60	197.78	269.02
5	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	16.41	(65.75)	(91.41)	(301.90)	33.60	(84.45)
6	Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit / (Loss) from ordinary activities before exceptional items (5-6)	16.41	(65.75)	(91.41)	(301.90)	33.60	(84.45)
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7+8)	16.41	(65.75)	(91.41)	(301.90)	33.60	(84.45)
10	Tax Expenses						
	Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred Tax	(18.98)	(15.67)	(16.38)	(38.17)	(74.59)	(65.90)
	Tax Adjustments of Earlier years	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit / (Loss) from ordinary activities after tax (9-10)	35.39	(50.08)	(75.03)	(263.73)	108.19	(18.55)
12	Extra Ordinary Items (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11+12)	35.39	(50.08)	(75.03)	(263.73)	108.19	(18.55)
14	Paid-Up equity share capital (Face Value Rs 10 per share)	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18
15	Reserve excluding Revaluation Reserve [As per the latest Audited Balance Sheet]						10674.36
16.i	Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised):						
	(a) Basic	0.27	(0.38)	(0.57)	(1.99)	0.82	(0.14)
	(b) Diluted	0.27	(0.38)	(0.57)	(1.99)	0.82	(0.14)
16.ii	Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised):						
	(a) Basic	0.27	(0.38)	(0.57)	(1.99)	0.82	(0.14)
	(b) Diluted	0.27	(0.38)	(0.57)	(1.99)	0.82	(0.14)

Notes:

- The above results as reviewed by the audit committee have been taken on record by the Board of Directors at their meeting held on 12th February, 2016.
- The Company has operated only in one reportable segment i.e. Pharmaceuticals.
- The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place : Mumbai
Date: 12th February, 2016



Mukund P. Mehta
Managing Director